Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results